In 2019, a Phase I/II clinical trial recruiting advanced solid tumor patients, including 6 NSCLC patients, combined ICB with a heterologous vaccination strategy combining chimp adenovirus (ChAd68) and self-replicating RNA (srRNA) coding for 20 shared neoantigens derived from common KRAS and TRP53 mutations [176]. Here, KRAS is linked to non-small cell lung carcinoma.